



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated December 03, 2024

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Update on US FDA inspection at Gagillapur Facility

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Mam,

This is regarding our communication dated September 07, 2024, about the US FDA inspection of the Company's facility at Gagillapur, Hyderabad, Telangana and the issuance of Form 483 with 6 observations.

We further inform you that the US FDA has classified the inspection as "Official Action Indicated" (OAI).

The Company has responded to all the observations issued by the US FDA. Additionally, the Company has voluntarily undertaken a comprehensive evaluation of the facility for further enhancements that lead to improvement of the facility. This activity is undertaken in consultation with external subject matter experts.

The Company will work with the US FDA on this activity and is confident that it will result in the US FDA approving the Company's facility at Gagillapur in compliance with its expectations within a short time.

This is for your information and dissemination to the members of the exchange.

Thanking You.

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**